Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Express Scripts
Moodys
AstraZeneca
Mallinckrodt

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Emricasan

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Emricasan: Patents, clinical trial progress, indications

Emricasan is an investigational drug.

There have been 12 clinical trials for Emricasan. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Fibrosis, Liver Cirrhosis, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Conatus Pharmaceuticals Inc., National Institute on Alcohol Abuse and Alcoholism (NIAAA), and University of Alberta.

There are seven US patents protecting this investigational drug and eighty-three international patents.

Recent Clinical Trials for Emricasan
TitleSponsorPhase
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH CirrhosisConatus Pharmaceuticals Inc.Phase 2
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal HypertensionConatus Pharmaceuticals Inc.Phase 2
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) FibrosisConatus Pharmaceuticals Inc.Phase 2

See all Emricasan clinical trials

Clinical Trial Summary for Emricasan

Top disease conditions for Emricasan
Top clinical trial sponsors for Emricasan

See all Emricasan clinical trials

US Patents for Emricasan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Emricasan   Start Trial C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases Idun Pharmaceuticals, Inc. (La Jolla, CA)   Start Trial
Emricasan   Start Trial C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases Idun Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Emricasan   Start Trial C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases Idun Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Emricasan   Start Trial C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases Idun Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Emricasan

Drugname Country Document Number Estimated Expiration Related US Patent
Emricasan Austria 348096 2018-07-02   Start Trial
Emricasan Austria 442843 2018-07-02   Start Trial
Emricasan Australia 4856999 2018-07-02   Start Trial
Emricasan Australia 752339 2018-07-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Express Scripts
Boehringer Ingelheim
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.